Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series

Jason S. Baker, Patrick J. Nolan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background The aim of this study is to evaluate the effectiveness of botulinum toxin type A (BTX-A) for the treatment of chronic masticatory myofascial pain (MMP) over 12 months and to test a standardized protocol. Methods This is a prospective case series of consecutive adult patients with chronic MMP treated with injection of BTX-A into the bilateral temporalis and masseter muscles. The authors used the same anatomic landmarks and dosage and followed each patient for 12 months. The primary outcome variables were reduction in pain measured with visual analog scale (VAS) and Physician Global Assessment (PGA). Secondary outcome variables were change in maximum pain-free opening, change in palpatory pain points in the face and oral cavity, and change in results from a questionnaire measuring disability, dysfunction, and psychosocial effects of the disease. Results The authors included 15 women and 4 men (mean [standard deviation] age, 32.7 [6.9] years) in the study. Pain decreased significantly as measured with the VAS (P <.0001) and PGA (P <.0001). Maximum pain-free opening increased significantly (P =.010), but maximum voluntary opening did not change significantly (P =.837). The number of palpatory pain points (P <.0001) and the symptom questionnaire score decreased over time (P <.0001). Conclusions The results of this case series suggest that injecting BTX-A into the bilateral temporalis and masseter muscles may be a safe and effective treatment for chronic MMP. Practical Implications Controlled clinical trials are needed to confirm whether administration of BTX-A is effective in treating facial pain.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalJournal of the American Dental Association
Volume148
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Type A Botulinum Toxins
Pain
Masseter Muscle
Visual Analog Scale
Therapeutics
Anatomic Landmarks
Physicians
Facial Pain
Controlled Clinical Trials
Injections

Keywords

  • botulinum toxin
  • clinical protocols
  • myalgia
  • Myofascial pain
  • orofacial
  • pain

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

@article{b88bef7d6cd14f88b1b25c4865453aa3,
title = "Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series",
abstract = "Background The aim of this study is to evaluate the effectiveness of botulinum toxin type A (BTX-A) for the treatment of chronic masticatory myofascial pain (MMP) over 12 months and to test a standardized protocol. Methods This is a prospective case series of consecutive adult patients with chronic MMP treated with injection of BTX-A into the bilateral temporalis and masseter muscles. The authors used the same anatomic landmarks and dosage and followed each patient for 12 months. The primary outcome variables were reduction in pain measured with visual analog scale (VAS) and Physician Global Assessment (PGA). Secondary outcome variables were change in maximum pain-free opening, change in palpatory pain points in the face and oral cavity, and change in results from a questionnaire measuring disability, dysfunction, and psychosocial effects of the disease. Results The authors included 15 women and 4 men (mean [standard deviation] age, 32.7 [6.9] years) in the study. Pain decreased significantly as measured with the VAS (P <.0001) and PGA (P <.0001). Maximum pain-free opening increased significantly (P =.010), but maximum voluntary opening did not change significantly (P =.837). The number of palpatory pain points (P <.0001) and the symptom questionnaire score decreased over time (P <.0001). Conclusions The results of this case series suggest that injecting BTX-A into the bilateral temporalis and masseter muscles may be a safe and effective treatment for chronic MMP. Practical Implications Controlled clinical trials are needed to confirm whether administration of BTX-A is effective in treating facial pain.",
keywords = "botulinum toxin, clinical protocols, myalgia, Myofascial pain, orofacial, pain",
author = "Baker, {Jason S.} and Nolan, {Patrick J.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.adaj.2016.09.013",
language = "English (US)",
volume = "148",
pages = "33--39",
journal = "Journal of the American Dental Association",
issn = "0002-8177",
publisher = "American Dental Association",
number = "1",

}

TY - JOUR

T1 - Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain

T2 - A case series

AU - Baker, Jason S.

AU - Nolan, Patrick J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background The aim of this study is to evaluate the effectiveness of botulinum toxin type A (BTX-A) for the treatment of chronic masticatory myofascial pain (MMP) over 12 months and to test a standardized protocol. Methods This is a prospective case series of consecutive adult patients with chronic MMP treated with injection of BTX-A into the bilateral temporalis and masseter muscles. The authors used the same anatomic landmarks and dosage and followed each patient for 12 months. The primary outcome variables were reduction in pain measured with visual analog scale (VAS) and Physician Global Assessment (PGA). Secondary outcome variables were change in maximum pain-free opening, change in palpatory pain points in the face and oral cavity, and change in results from a questionnaire measuring disability, dysfunction, and psychosocial effects of the disease. Results The authors included 15 women and 4 men (mean [standard deviation] age, 32.7 [6.9] years) in the study. Pain decreased significantly as measured with the VAS (P <.0001) and PGA (P <.0001). Maximum pain-free opening increased significantly (P =.010), but maximum voluntary opening did not change significantly (P =.837). The number of palpatory pain points (P <.0001) and the symptom questionnaire score decreased over time (P <.0001). Conclusions The results of this case series suggest that injecting BTX-A into the bilateral temporalis and masseter muscles may be a safe and effective treatment for chronic MMP. Practical Implications Controlled clinical trials are needed to confirm whether administration of BTX-A is effective in treating facial pain.

AB - Background The aim of this study is to evaluate the effectiveness of botulinum toxin type A (BTX-A) for the treatment of chronic masticatory myofascial pain (MMP) over 12 months and to test a standardized protocol. Methods This is a prospective case series of consecutive adult patients with chronic MMP treated with injection of BTX-A into the bilateral temporalis and masseter muscles. The authors used the same anatomic landmarks and dosage and followed each patient for 12 months. The primary outcome variables were reduction in pain measured with visual analog scale (VAS) and Physician Global Assessment (PGA). Secondary outcome variables were change in maximum pain-free opening, change in palpatory pain points in the face and oral cavity, and change in results from a questionnaire measuring disability, dysfunction, and psychosocial effects of the disease. Results The authors included 15 women and 4 men (mean [standard deviation] age, 32.7 [6.9] years) in the study. Pain decreased significantly as measured with the VAS (P <.0001) and PGA (P <.0001). Maximum pain-free opening increased significantly (P =.010), but maximum voluntary opening did not change significantly (P =.837). The number of palpatory pain points (P <.0001) and the symptom questionnaire score decreased over time (P <.0001). Conclusions The results of this case series suggest that injecting BTX-A into the bilateral temporalis and masseter muscles may be a safe and effective treatment for chronic MMP. Practical Implications Controlled clinical trials are needed to confirm whether administration of BTX-A is effective in treating facial pain.

KW - botulinum toxin

KW - clinical protocols

KW - myalgia

KW - Myofascial pain

KW - orofacial

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=85005976182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005976182&partnerID=8YFLogxK

U2 - 10.1016/j.adaj.2016.09.013

DO - 10.1016/j.adaj.2016.09.013

M3 - Article

C2 - 28314397

AN - SCOPUS:85005976182

VL - 148

SP - 33

EP - 39

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

SN - 0002-8177

IS - 1

ER -